Yin Wen, Zhu Hecheng, Tan Jun, Xin Zhaoqi, Zhou Quanwei, Cao Yudong, Wu Zhaoping, Wang Lei, Zhao Ming, Jiang Xingjun, Ren Caiping, Tang Guihua
Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, Hunan Province, 410008, China.
Changsha Kexin Cancer Hospital, Changsha, Hunan, 410205, China.
Cancer Cell Int. 2021 May 25;21(1):276. doi: 10.1186/s12935-021-01982-0.
Gliomas account for the majority of fatal primary brain tumors, and there is much room for research in the underlying pathogenesis, the multistep progression of glioma, and how to improve survival. In our study, we aimed to identify potential biomarkers or therapeutic targets of glioma and study the mechanism underlying the tumor progression.
We downloaded the microarray datasets (GSE43378 and GSE7696) from the Gene Expression Omnibus (GEO) database. Then, we used weighted gene co-expression network analysis (WGCNA) to screen potential biomarkers or therapeutic targets related to the tumor progression. ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumors using Expression data) algorithm and TIMER (Tumor Immune Estimation Resource) database were used to analyze the correlation between the selected genes and the tumor microenvironment. Real-time reverse transcription polymerase chain reaction was used to measure the selected gene. Transwell and wound healing assays were used to measure the cell migration and invasion capacity. Western blotting was used to test the expression of epithelial-mesenchymal transition (EMT) related markers.
We identified specific module genes that were positively correlated with the WHO grade but negatively correlated with OS of glioma. Importantly, we identified that 6 collagen genes (COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, and COL5A2) could regulate the immunosuppressive microenvironment of glioma. Moreover, we found that these collagen genes were significantly involved in the EMT process of glioma. Finally, taking COL3A1 as a further research object, the results showed that knockdown of COL3A1 significantly inhibited the migration, invasion, and EMT process of SHG44 and A172 cells.
In summary, our study demonstrated that collagen genes play an important role in regulating the immunosuppressive microenvironment and EMT process of glioma and could serve as potential therapeutic targets for glioma management.
胶质瘤是致命原发性脑肿瘤的主要类型,在其潜在发病机制、胶质瘤的多步骤进展以及如何提高生存率方面仍有很大的研究空间。在我们的研究中,我们旨在识别胶质瘤的潜在生物标志物或治疗靶点,并研究肿瘤进展的潜在机制。
我们从基因表达综合数据库(GEO)下载了微阵列数据集(GSE43378和GSE7696)。然后,我们使用加权基因共表达网络分析(WGCNA)来筛选与肿瘤进展相关的潜在生物标志物或治疗靶点。使用ESTIMATE(利用表达数据估计恶性肿瘤中的基质和免疫细胞)算法和TIMER(肿瘤免疫估计资源)数据库来分析所选基因与肿瘤微环境之间的相关性。使用实时逆转录聚合酶链反应来测量所选基因。使用Transwell和伤口愈合试验来测量细胞迁移和侵袭能力。使用蛋白质免疫印迹法检测上皮-间质转化(EMT)相关标志物的表达。
我们鉴定出与世界卫生组织(WHO)分级呈正相关但与胶质瘤总生存期呈负相关的特定模块基因。重要的是,我们发现6种胶原蛋白基因(COL1A1、COL1A2、COL3A1、COL4A1、COL4A2和COL5A2)可调节胶质瘤的免疫抑制微环境。此外,我们发现这些胶原蛋白基因显著参与了胶质瘤的EMT过程。最后,以COL3A1作为进一步的研究对象,结果表明敲低COL3A1可显著抑制SHG44和A172细胞的迁移、侵袭和EMT过程。
总之,我们的研究表明胶原蛋白基因在调节胶质瘤的免疫抑制微环境和EMT过程中起重要作用,可作为胶质瘤治疗的潜在靶点。